All Stories

  1. NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring

    Article • PLoS ONE, March 2021, PLOS

    Professor Vladimir V Rafalskiy

  2. Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by Surface-enhanced Raman spectroscopy

    Article • Data in Brief, January 2020, Elsevier

    Professor Vladimir V Rafalskiy

  3. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor John GF Cleland

  4. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  5. Distribution and antibiotic resistance profile of key gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study

    Article • Journal of Global Antimicrobial Resistance, September 2019, Elsevier

    Professor Vladimir V Rafalskiy

  6. Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation

    Article • Urology Herald, October 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  7. Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

    Article • European Journal of Heart Failure, September 2018, Wiley

    Professor Vladimir V Rafalskiy

  8. EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION

    Article • Urology Herald, July 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  9. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

    Article • Diabetes Mellitus, February 2018, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  10. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation

    Article • Circulation Heart Failure, October 2017, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy

  11. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2017, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  12. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF

    Article • American Heart Journal, June 2017, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  13. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2)

    Article • Diabetes Mellitus, March 2017, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  14. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

    Article • Diabetes Obesity and Metabolism, January 2017, Wiley

    Professor Vladimir V Rafalskiy

  15. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

    Article • European Journal of Heart Failure, November 2016, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  16. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial

    Article • International Journal of Infectious Diseases, September 2016, Elsevier

    Professor Vladimir V Rafalskiy

  17. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, September 2016, Wolters Kluwer Health

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  18. Sharing Data from Cardiovascular Clinical Trials — A Proposal

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2016, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  19. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

    Article • Journal of the American College of Cardiology, July 2016, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  20. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE

    Article • Circulation, April 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  21. Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, January 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  22. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, December 2015, Wiley

    Professor Vladimir V Rafalskiy

  23. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Francisco Marin

  24. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  25. Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores

    Article • Journal of the American College of Cardiology, November 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  26. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

    Article • European Heart Journal, July 2015, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  27. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

    Article • American Heart Journal, May 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Tzung-Dau Wang, Professor Rayaz Ahmed Malik, Francisco Marin

  28. Pharmacokinetic peculiarities of intravenous and oral ciprofloxacin administration in preoperative prophylaxis in patients with benign prostatic hyperplasia

    Article • Reviews on Clinical Pharmacology and Drug Therapy, December 2014, ECO-Vector LLC

    Professor Vladimir V Rafalskiy

  29. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

    Article • Diabetes Care, December 2014, American Diabetes Association

    Professor Vladimir V Rafalskiy

  30. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

    Article • European Heart Journal, November 2014, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  31. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

    Article • Circulation, November 2014, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  32. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  33. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

    Article • The Lancet, August 2014, Elsevier

    Professor Vladimir V Rafalskiy

  34. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

    Article • European Journal of Heart Failure, June 2014, Wiley

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  35. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

    Article • Hepatology, October 2013, Wiley

    Professor Vladimir V Rafalskiy

  36. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

    Article • European Journal of Heart Failure, September 2013, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Dr William D Strain

  37. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Professor Vladimir V Rafalskiy

  38. Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

    Article • Gastroenterology, May 2013, Elsevier

    Professor Vladimir V Rafalskiy

  39. 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Vladimir V Rafalskiy

  40. Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease

    Article • Clinical Gastroenterology and Hepatology, March 2013, Elsevier

    Professor Vladimir V Rafalskiy

  41. Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2012, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  42. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

    Article • Hepatology, August 2010, Wiley

    Professor Vladimir V Rafalskiy

  43. 247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Vladimir V Rafalskiy

  44. P300 Does in vitro antimicrobial resistance predict clinical outcomes in urinary tract infections: systematic review and metaanalysis

    Article • International Journal of Antimicrobial Agents, July 2009, Elsevier

    Professor Vladimir V Rafalskiy

  45. PREVALENCE AND RISK FACTORS OF UNCOMPLICATED UTI: MULTICENTRE STUDY SONAR

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  46. 3-5 DAYS FLUOROQUINOLONES THERAPY IS MORE EFFECTIVE FOR ACUTE UNCOMPLICATED CYSTITIS THEN SINGLE DOSE FOSFOMYCIN: SYSTEMATIC REVIEW AND META-ANALYSIS

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  47. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2

    Article • International Journal of Antimicrobial Agents, August 2006, Elsevier

    Professor Vladimir V Rafalskiy

  48. Quinolones for uncomplicated acute cystitis in women

    Article • Cochrane Database of Systematic Reviews, July 2006, Wiley

    Professor Vladimir V Rafalskiy

  49. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Daniel D Shouval, Professor Vladimir V Rafalskiy

  50. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  51. Quinolones for uncomplicated acute cystitis in women

    Article • April 2002, Wiley

    Professor Vladimir V Rafalskiy